Evidence map›Paper›PMID 37186066›Full record

ArticleESC heart failure2023

Circulating immune checkpoints predict heart failure outcomes.

Elles M Screever, Laura I E Yousif, Javid J Moslehi, Joe-Elie Salem, Adriaan A Voors, Herman H W Silljé, Rudolf A de Boer, Wouter C Meijers

Open access · goldAbstract read
In one paragraph

Article in ESC heart failure, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 14 citations in OpenAlex.

  1. TIM-3 in Cardiovascular Disease.Current heart failure reports · 2026
    Review
  2. Review
  3. 2024 update in heart failure.ESC heart failure · 2025
    Review
  4. Review
  5. Review
  6. Article
  7. Genetic factors in the pathogenesis of cardio-oncology.Journal of translational medicine · 2024
    Review
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 3 countries.

Elles M ScreeverDepartment of Cardiology, University Medical Center Groningen, Groningen, The Netherlands.
Laura I E YousifDivision of Experimental Cardiology, Department of Cardiology, Thorax Center, Erasmus University Medical Center, PO Box 2040, 3000CA, Rotterdam, The Netherlands.
Javid J MoslehiSection of Cardio-Oncology and Immunology, Division of Cardiology and the Cardiovascular Research Institute, University of California San Francisco, San Francisco, CA, USA.
Joe-Elie SalemDepartment of Pharmacology, Assistance Publique-Hôpitaux de Paris (AP-HP), Sorbonne Université, INSERM, CIC-1901, UNICO-GRECO Cardio-oncology Program, Paris, France.
Adriaan A VoorsDepartment of Cardiology, University Medical Center Groningen, Groningen, The Netherlands.
Herman H W SilljéDepartment of Cardiology, University Medical Center Groningen, Groningen, The Netherlands.
Rudolf A de BoerDepartment of Cardiology, University Medical Center Groningen, Groningen, The Netherlands.
Wouter C MeijersDepartment of Cardiology, University Medical Center Groningen, Groningen, The Netherlands.
University Medical Center Groningen · NLErasmus University Rotterdam · NLErasmus MC · NLUniversité Paris Cité · FRUniversity of California, San Francisco · US

Funding

European Research Council ERC CoG 818715
6 · The paper itself

Abstract

aimsThere are limited data examining the role of immune checkpoint (IC) ligands in the pathophysiology of heart failure (HF). Therefore, we explore this in three HF animal models and in three different human cohorts (healthy, stable, and worsening HF). METHODS AND

resultsTranscriptomic analyses of cardiac tissue of three different HF mouse models revealed differentially expressed IC receptors and their ligands compared with control mice. Based on this observation, serum levels of three well-known IC ligands (i.e. sPD-L1, sPD-L2 and galectin-9) were measured in stable HF patients from the Vitamin D Chronic Heart Failure (VitD-CHF) study (n = 101), as well as healthy individuals from the Prevention of Renal and Vascular End-stage Disease (PREVEND) study (n = 58). sPD-L1, sPD-L2, and galectin-9 were all associated with New York Heart Association classification. In multivariate linear regression analyses, all three IC ligands were associated with galectin-3 (β = 0.230, β = 0.283, and β = 0.304, respectively). sPD-L1 and galectin-9 were also associated with hs-troponin-T (β = 0.386 and β = 0.314). Regarding prognosis, higher serum levels of sPD-L1 and galectin-9 were significantly associated with increased risk for HF hospitalization and all-cause mortality [hazard ratio 1.69 (1.09-2.59) and hazard ratio 1.50 (1.06-2.12)]. Furthermore, the importance of IC ligands was tested in another stage of HF, namely worsening HF patients. In the worsening HF cohort (The BIOlogy Study to Tailored Treatment in Chronic Heart Failure) (n = 2032), sPD-L2 and galectin-9 were associated with New York Heart Association classification and significantly predicted outcome with an increased relative risk of 15% and 20%, after multivariable adjustment, respectively.

conclusionsIC ligands are expressed in cardiac disease models, and serum levels of IC ligands are elevated in HF patients, are associated with disease severity, and significantly predict prognosis. These data indicate a potential role for IC ligands in HF pathogenesis.

Indexed as

Heart FailureAnimalsChronic DiseaseGalectin 3GalectinsHumansLigandsMicePrognosisGalectin 3GalectinsLigandsGalectin-9Heart failureImmune checkpointsPD-L1PD-L2

Identifiers

PMID37186066
PMCPMC10375122
OpenAlexW4367054718

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.